Leptospira Medium Base, Korthof
To Order Contact us: lieven@wlsolutions.be
Gc Medium Base 500gm |
||
| 228950 | EACH | EUR 157.32 |
NBS Innova 44 Medium Base 330mm |
||
| SHA1112 | EACH | EUR 1377.12 |
Qual Set Base Cont Medium Range 1.0M to 3.0M |
||
| AQSB002 | 250ML | EUR 265.62 |
casting base |
||
| EHS3100-CAST | ea | EUR 128.4 |
casting base |
||
| EHS3200-CAST | ea | EUR 148.8 |
casting base |
||
| EHS3300-CAST | ea | EUR 148.8 |
Tris-base |
||
| 20-abx082498 |
|
|
Tetracycline base |
||
| GA9779-100G | 100 g | EUR 180 |
Tetracycline base |
||
| GA9779-10G | 10 g | EUR 55.2 |
Tetracycline base |
||
| GA9779-25G | 25 g | EUR 74.4 |
Rimonabant base |
||
| GX9120-10MG | 10 mg | EUR 103.2 |
Rimonabant base |
||
| GX9120-25MG | 25 mg | EUR 156 |
ProteoIQ Base |
||
| PS2 | 1 | EUR 5114.4 |
Vincamine base |
||
| Q-1435.0005 | 5.0g | EUR 270 |
|
Description: Sum Formula: C21H26N2O3; CAS# [1617-90-9] |
||
Vincamine base |
||
| Q-1435.0025 | 25.0g | EUR 963.6 |
|
Description: Sum Formula: C21H26N2O3; CAS# [1617-90-9] |
||
Positioning Base |
||
| S44I041002 | EACH | EUR 1409.04 |
Channel Base |
||
| C653 | EACH | EUR 22.46 |
Leptospira antibody |
||
| 10-1293 | 500 ug | EUR 571.2 |
|
Description: Mouse monoclonal Leptospira antibody |
||
A Medium |
||
| DJ1018 | 100g | EUR 101.76 |
DC MEDIUM |
||
| D04-117-10kg | 10 kg | EUR 1894.8 |
DC MEDIUM |
||
| D04-117-2kg | 2kg | EUR 458.4 |
DC MEDIUM |
||
| D04-117-500g | 500 g | EUR 168 |
Advanced Medium |
||
| C0003-04 | RT 500 mL Bottle | EUR 123.6 |
Medium 199 |
||
| C0012-01 | RT 500 mL Bottle | EUR 126 |
COLIFORM MEDIUM |
||
| C03-127-10kg | 10 kg | EUR 1588.8 |
COLIFORM MEDIUM |
||
| C03-127-2kg | 2kg | EUR 392.4 |
COLIFORM MEDIUM |
||
| C03-127-500g | 500 g | EUR 150 |
Heller's Medium |
||
| CP014-010 | 10X1L | EUR 118.8 |
Heller's Medium |
||
| CP014-500 | 50L | EUR 151.2 |
Hoagland's Medium |
||
| CP015-010 | 10X1L | EUR 118.8 |
Hoagland's Medium |
||
| CP015-500 | 50L | EUR 151.2 |
EC MEDIUM |
||
| E05-100-10kg | 10 kg | EUR 976.8 |
EC MEDIUM |
||
| E05-100-2Kg | 2 Kg | EUR 259.2 |
EC MEDIUM |
||
| E05-100-500g | 500 g | EUR 114 |
Mounting Medium |
||
| 4300 | 3 ml | EUR 216.6 |
|
Description: This is Mounting medium (non-fading) used for maintaining optimal conditions needed to obtain the maximum fluorescence emission from Fluorescein. |
||
NeuroProgenitor Medium |
||
| NM42400 | 125 ml | EUR 364.8 |
HLP MEDIUM |
||
| H08-107-10kg | 10 kg | EUR 2733.6 |
HLP MEDIUM |
||
| H08-107-2Kg | 2 Kg | EUR 640.8 |
HLP MEDIUM |
||
| H08-107-500g | 500 g | EUR 218.4 |
SIM MEDIUM |
||
| S19-110-10kg | 10 kg | EUR 1225.2 |
SIM MEDIUM |
||
| S19-110-2kg | 2kg | EUR 313.2 |
SIM MEDIUM |
||
| S19-110-500g | 500 g | EUR 128.4 |
SOB MEDIUM |
||
| S19-124-10kg | 10 kg | EUR 1158 |
SOB MEDIUM |
||
| S19-124-2kg | 2kg | EUR 298.8 |
SOB MEDIUM |
||
| S19-124-500g | 500 g | EUR 124.8 |
M9 Medium |
||
| SD7024 | 250g | EUR 86.1 |
M9CA Medium |
||
| SD7025 | 250g | EUR 86.1 |
YM Medium |
||
| SD7031 | 250g | EUR 84.54 |
TYGPN Medium |
||
| SD7032 | 250g | EUR 84.01 |
M63 Medium |
||
| SD7033 | 250g | EUR 86.1 |
TCBS Medium |
||
| MED1188 | PK10 | EUR 7.52 |
DNase Medium |
||
| MED1196 | PK10 | EUR 7.98 |
OF Medium |
||
| MED1664 | 500G | EUR 68.4 |
Rucaparib (free base) |
||
| A8893-10 | 10 mg | EUR 240 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-200 | 200 mg | EUR 1243.2 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-5 | 5 mg | EUR 164.4 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-5.1 | 10 mM (in 1mL DMSO) | EUR 170.4 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-50 | 50 mg | EUR 547.2 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
R406 (free base) |
||
| A5880-100 | 100 mg | EUR 1452 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-25 | 25 mg | EUR 616.8 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-5 | 5 mg | EUR 199.2 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-5.1 | 10 mM (in 1mL DMSO) | EUR 316.8 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-S | Evaluation Sample | EUR 97.2 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
CETRIMIDE AGAR BASE |
||
| C03-107-10kg | 10 kg | EUR 1474.8 |
CETRIMIDE AGAR BASE |
||
| C03-107-2Kg | 2 Kg | EUR 367.2 |
CETRIMIDE AGAR BASE |
||
| C03-107-500g | 500 g | EUR 144 |
AZD4547, Free Base |
||
| ADC-P-063 | unit | Ask for price |
AZD8055, Free Base |
||
| ADC-P-064 | unit | Ask for price |
Cyclopamine, Free Base |
||
| ADC-P-079 | unit | Ask for price |
Ixabepilone, Free Base |
||
| ADC-P-104 | unit | Ask for price |
R406(free base) |
||
| E1KS1533 | 2mg | EUR 625.2 |
Ruxolitinib (free base) |
||
| 10-042 | 25 mg | EUR 418.2 |
|
Description: Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. It is investigated against the spread of the SARS-CoV-2 (COVID-19). |
||
LY2835219 free base |
||
| A3575-100 | 100 mg | EUR 686.4 |
|
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
||
LY2835219 free base |
||
| A3575-25 | 25 mg | EUR 309.6 |
|
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
||
LY2835219 free base |
||
| A3575-5 | 5 mg | EUR 170.4 |
|
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
||
PLX5622 (free base) |
||
| B2965-25 | 25 mg | EUR 903.6 |
PLX5622 (free base) |
||
| B2965-5 | 5 mg | EUR 272.4 |
MYCOPLASMA BROTH BASE |
||
| M13-136-10kg | 10 kg | EUR 2108.4 |
MYCOPLASMA BROTH BASE |
||
| M13-136-2kg | 2kg | EUR 505.2 |
MYCOPLASMA BROTH BASE |
||
| M13-136-500g | 500 g | EUR 181.2 |
PURPLE BROTH BASE |
||
| P16-117-10kg | 10 kg | EUR 2005.2 |
PURPLE BROTH BASE |
||
| P16-117-2kg | 2kg | EUR 482.4 |
PURPLE BROTH BASE |
||
| P16-117-500g | 500 g | EUR 175.2 |
LETHEEN AGAR BASE |
||
| L12-108-10kg | 10 kg | EUR 1801.2 |
LETHEEN AGAR BASE |
||
| L12-108-2Kg | 2 Kg | EUR 438 |
LETHEEN AGAR BASE |
||
| L12-108-500g | 500 g | EUR 163.2 |
LETHEEN BROTH BASE |
||
| L12-109-10kg | 10 kg | EUR 1504.8 |
LETHEEN BROTH BASE |
||
| L12-109-2kg | 2kg | EUR 374.4 |
LETHEEN BROTH BASE |
||
| L12-109-500g | 500 g | EUR 145.2 |
YM158 (free base) |
||
| HY-U00355 | 1mg | EUR 2770.8 |
Bisindolylmaleimide I base |
||
| GL2668-1MG | 1 mg | EUR 164.4 |
Bisindolylmaleimide I base |
||
| GL2668-5MG | 5 mg | EUR 322.8 |
BIX 01294 base |
||
| GL8747-1MG | 1 mg | EUR 127.2 |
BIX 01294 base |
||
| GL8747-25MG | 25 mg | EUR 490.8 |
BIX 01294 base |
||
| GL8747-5MG | 5 mg | EUR 218.4 |
Fuchsine base (monohydrochloride) |
||
| HY-B1539A | 1g | EUR 142.8 |